Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.95)
# 1,597
Out of 4,749 analysts
44
Total ratings
25%
Success rate
7.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VYGR Voyager Therapeutics | Initiates: Overweight | $5.73 | $5.45 | +5.14% | 1 | Jan 10, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $16.97 | - | 5 | Dec 16, 2024 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $8.91 | - | 1 | Dec 9, 2024 | |
| ALEC Alector | Reiterates: Overweight | n/a | $1.66 | - | 5 | Nov 26, 2024 | |
| ANNX Annexon | Reiterates: Overweight | n/a | $3.84 | - | 9 | Nov 15, 2024 | |
| VSTM Verastem | Reiterates: Overweight | n/a | $6.08 | - | 1 | Oct 18, 2024 | |
| VERA Vera Therapeutics | Reiterates: Overweight | $107 | $37.28 | +187.02% | 7 | Oct 3, 2024 | |
| PLRX Pliant Therapeutics | Reiterates: Overweight | n/a | $10.75 | - | 4 | Aug 8, 2024 | |
| DNTH Dianthus Therapeutics | Initiates: Overweight | n/a | $22.15 | - | 1 | Jun 27, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Overweight | n/a | $6.06 | - | 4 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $5.25 | -4.76% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.50 | +766.67% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $11.03 | -27.47% | 1 | Mar 20, 2023 |
Voyager Therapeutics
Jan 10, 2025
Initiates: Overweight
Price Target: $5.73
Current: $5.45
Upside: +5.14%
Arcturus Therapeutics Holdings
Dec 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.97
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.91
Upside: -
Alector
Nov 26, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.66
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.84
Upside: -
Verastem
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.08
Upside: -
Vera Therapeutics
Oct 3, 2024
Reiterates: Overweight
Price Target: $107
Current: $37.28
Upside: +187.02%
Pliant Therapeutics
Aug 8, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.75
Upside: -
Dianthus Therapeutics
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $22.15
Upside: -
Jasper Therapeutics
Jun 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.06
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $5.25
Upside: -4.76%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $1.50
Upside: +766.67%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $11.03
Upside: -27.47%